SHL Telemedicine Ltd. (SHLT)

Market Cap	45.91M
Revenue (ttm)	55.94M
Net Income (ttm)	-8.84M
Shares Out	16.39M
EPS (ttm)	-0.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,584
Open	2.627
Previous Close	2.630
Day's Range	2.627 - 2.720
52-Week Range	2.540 - 9.410
Beta	0.40
Analysts	Strong Buy
Price Target	11.00 (+304.41%)
Earnings Date	Sep 26, 2024

About SHLT

SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. It offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen’C, a personal cellular-digital 12-lead ECG transmitter device; and Cardio’B, a portable device to transmit a 12-lead ECG. The company also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monito...

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 1987
• Employees: 583
• Stock Exchange: NASDAQ
• Ticker Symbol: SHLT
• Website: https://www.shl-telemedicine.com

Financial Performance

In 2023, SHL Telemedicine's revenue was $57.08 million, a decrease of -3.26% compared to the previous year's $59.00 million. Losses were -$7.06 million, 9184.2% more than in 2022.

Analyst Forecast

According to one analyst, the rating for SHLT stock is "Strong Buy" and the 12-month stock price forecast is $11.0.

Price Target

$11.0

(304.41% upside)

Analyst Consensus: Strong Buy